RT Journal Article
T1 Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
A1 Schattenberg, Jörn M
A1 Lazarus, Jeffrey V
A1 Newsome, Philip N
A1 Serfaty, Lawrence
A1 Aghemo, Alessio
A1 Augustin, Salvador
A1 Tsochatzis, Emmanuel
A1 de Ledinghen, Victor
A1 Bugianesi, Elisabetta
A1 Romero-Gomez, Manuel
A1 Bantel, Heike
A1 Ryder, Stephen D
A1 Boursier, Jerome
A1 Leroy, Vincent
A1 Crespo, Javier
A1 Castera, Laurent
A1 Floros, Lefteris
A1 Atella, Vincenzo
A1 Mestre-Ferrandiz, Jorge
A1 Elliott, Rachel
A1 Kautz, Achim
A1 Morgan, Alice
A1 Hartmanis, Sally
A1 Vasudevan, Sharad
A1 Pezzullo, Lynne
A1 Trylesinski, Aldo
A1 Cure, Sandrine
A1 Higgins, Victoria
A1 Ratziu, Vlad
K1 burden of disease
K1 cost-of-illness analysis
K1 economic impact
K1 healthcare resource utilisation
K1 non-alcoholic steatohepatitis (NASH)
AB Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom in 2018. The socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on a literature review, databases and consultation with clinical experts, economists and patient groups. The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8%-39.1% for advanced fibrosis (F3-F4 compensated cirrhosis). Total economic costs were €8548-19 546M. Of these, health system costs were €619-1292M. Total wellbeing costs were €41 536-90 379M. The majority of the undiagnosed population (87.3%-88.2% of total prevalence) was found to have early-stage NASH, which, left untreated, may progress to more resource consuming ESLD over time. This study found that the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.
YR 2021
FD 2021-03-18
LK http://hdl.handle.net/10668/17185
UL http://hdl.handle.net/10668/17185
LA en
DS RISalud
RD Apr 4, 2025